VNB margin recovery offsets weak APE growth; regulatory headwinds loom
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
VNB margin guidance (mid-20s) achieved at 22.3%; APE acceleration guidance missed—grew 3.2%, not accelerating. PAT +20% met.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
LIC posted solid VNB and margin expansion—hitting mid-20s guidance—but APE growth remains tepid (3.21%) despite promised ULIP recovery. Market share eroded slightly to 58.77%; regulatory uncertainty on distribution commission caps poses execution risk. Strong operational momentum is offset by macro-dependent growth headwinds.
₹13436.1 Cr
Revenue · +16.1% YoY₹12114.8 Cr
Reported PAT · +20% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
APE growth to accelerate in Q2+ as ULIP recovers
MISSH1 APE growth 3.21% (30,696 cr vs 29,744 cr); ULIP still declining 40%+; not accelerating
VNB margin expected to improve toward mid-20s
METVNB margin at 22.3% (up 470 bps YoY from 17.6%); target achieved
Protection business showing strong growth
METProtection APE growth 58.59% YoY; confirmed strong momentum
Market share stable in individual and group
OVERSTATEDMarket share down to 58.77% from 59.41% YoY; slight erosion
PAT growth 21.52% on H1 basis
METDelivered PAT YoY growth 20.0%; H1 claim aligns with annual metric
Earnings quality
What changed since the last call
VNB margin +470 bps YoY
UpgradeMargin at 22.3% (Sep 2026) vs 17.6% (Sep 2025). Driven by product mix shift to non-PAR, higher-margin pure protection, and operational efficiency gains. Aligns with mid-20s guidance.
APE growth stalled
DowngradeH1 APE up 3.21% (₹30,696 cr) vs 3.2% claimed acceleration in prior call. ULIP down 40%+, slowing individual APE. Group APE +14% but cannot offset ULIP drag. Missed implicit acceleration guidance.
Market share erosion
DowngradeMarket share by FYPIP dropped to 58.77% from 59.41% YoY (64 bps loss). Competition or slower growth in individual segment. Group market share stable at 70.45%.
Non-PAR mix compression
DowngradeNon-PAR APE share fell to 34.02% from 36.31%; PAR now 65.98%. Non-PAR savings up 35% but still losing portfolio share. Long-term margin support weakens if non-PAR shrinks.
Protection business inflection
UpgradePure protection APE up 58.59% (₹157 cr). New launches (Health Shield, Cancer Cover) driving traction. Small base but high-margin trajectory supports future profitability.
The Q&A
Analysts pressed hard on margin walk (non-PAR mix vs term business), ULIP recovery timing, and commission cap impact on agents. Management held firm on margin defense (product mix, expense ratio focus) and regulatory stance but deferred specifics to actuarial team. Tone was assured but somewhat repetitive.
Distribution regulation, commission impact — Avinash Singh, Emkay Global
PartialDistribution reform caps commission rate; LIC uniquely positioned via agent productivity focus, training, product mix shift. Will maintain competitive positioning despite commission cut.
VNB margin components and assumptions — Nischint Chawthe, Kotak Securities
AnsweredNon-PAR savings +350 bps (8% contribution), term growth +3%, RFR down 40 bps offset by business mix. Margin improvements from product interventions and operational efficiency, expected to improve further.
APE growth, product mix, non-PAR decline — Swarnabha Mukherjee, 360 ONE Capital
PartialProduct mix shift: high-ticket annuity, non-PAR savings, term business, protection growing. APE de-growth from ULIP temporary; market recovery expected, agents trained. Protection to drive long-term growth.
Annuity product growth, pricing — Mohit Mangal, Centrum
AnsweredNo IRR changes; annuity spread among many agents; single-premium focus to offset low-ticket monthly. Strategy to increase agent productivity and client base via annuity training.
Group business slowdown, ULIP mix drag — Mohit Mangal, Centrum
DodgedGroup APE +14%; market share down due to cyclical rate movements and competition. Interest rate cycles affect group pricing. Market share broadly stable; no near-term concern.
Bancassurance channel growth and partnership — Shobhit Sharma, Elara Securities
PartialBancassurance now favorable to LIC; added Yes Bank, RBL. IDBI stake sale reduces dependency (was 50%, now 30%). Expanding partnerships; traction expected as market improves.
ULIP outlook, market recovery timing — Prayesh Jain, Motilal Oswal
AnsweredULIP market-dependent; 30% of agents trained to sell ULIPs; recovery expected as market bounces. Growth muted current year but confident in rebound. Agents already positioned.
Office rationalization, expense ratio targets — Prayesh Jain, Motilal Oswal
PartialOngoing work; digital adoption and process re-engineering underway. Expect expense ratio improvements in coming quarters via higher centralization and automation.
Hedge and interest rate exposure on non-PAR book — Sanketh Godha, Avendus Spark
AnsweredHedge ~80% of premium; hardening rates help; maturity hedge ladder in place. Managed well under interest-rate environment; low near-term risk.
RBC capital, solvency outlook, dividend sustainability — Dipanjan Ghosh, Goldman Sachs
PartialSolvency ratio strong; pending RBC rules will guide capital actions. Focused on profitability and managing capital conservatively. Position ample for growth and potential dividend.
Guidance
No explicit FY27 revenue or APE numeric guidance
LowManagement discussed mid-20s VNB margin target and APE recovery pending ULIP market recovery; no FY27 revenue CAGR stated
VNB margin targeting mid-20s (achieved 22.3% H1)
HighMargin expansion driven by product mix (non-PAR, pure protection), operational efficiency (expense ratio controls), and yield tailwinds. Expected to improve further H2.
Risks the call surfaced
Regulatory — Distribution commission reform
HighIRDA consultation on agent commission caps; LIC relies heavily on agent channel (91.81% of new business). Commission cuts could reduce agent productivity, incentive alignment, and new policy sales.
Market — ULIP segment de-growth
HighULIP APE down >40% H1; market-driven weakness persists. APE growth promise (3%+) depends on ULIP recovery. If equity volatility continues, agents de-motivate, and growth targets missed.
Competitive — Market share erosion
MediumMarket share in individual FYPIP declined 64 bps YoY to 58.77%. Private players gaining in high-margin segments (annuity, pure protection). If trend continues, margin pressure or growth slowdown.
Financial — Non-PAR mix compression
MediumNon-PAR APE share fell to 34.02% from 36.31%. While individual non-PAR savings APE +35% YoY, portfolio share declining. Long-term VNB margin support weakens if non-PAR base shrinks relative to PAR.
Regulatory — RBC capital framework uncertainty
MediumRBC solvency guidelines pending finalization. Solvency ratio 2.35x is ample now, but final guidelines could tighten capital requirements. May force capital raise or constrain dividends/growth if rules unfavorable.
Management
Score 7/10. Clear on margin walk and product strategy; deferred detail on actuarial assumptions to Srivastava; withheld specifics on regulatory feedback. Transparent on market conditions, less so on internal targets. Track record mixed: VNB margin guidance (mid-20s) achieved at 22.3%; APE acceleration guidance missed (3.21% growth, not accelerating). PAT +20% met. Digital initiatives (MyLIC 4.7 rating, ANANDA +41%) executing well.
1 · H2 FY27
IRDA distribution regulation final guidance; impact on agent economics and channel growth unclear
2 · H2 FY27
New product ramp (Dhara-II, health shield, cancer cover); target 100k+ policies to offset ULIP weakness
3 · Sep 2026+
RBC solvency capital rules; may require capital raise or restrict growth if guidelines tighten
Strong operational momentum is offset by macro-dependent growth headwinds.
Informational and educational content only. Not investment advice.